Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 2838497A

Drug Profile

GSK 2838497A

Alternative Names: GSK 2231395A; GSK 2254232A; GSK 2254233A; GSK 2838500A; GSK 2838501A; GSK 2838502A; GSK 2838503A; GSK 2838504A; GSK 2838505A; GSK 2838506A; GSK 2838507A; GSK 2838508A; GSK2838497A; Non-typeable Haemophilus influenzae (NTHi) vaccine - GlaxoSmithKline; Non-typeable Haemophilus influenzae/pneumococcal adult vaccine - GlaxoSmithKline; NTHi-10-AS01E; NTHi-Pneumo

Latest Information Update: 15 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Haemophilus vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemophilus infections
  • No development reported Pneumococcal infections

Most Recent Events

  • 19 Apr 2017 GlaxoSmithKline completes the phase II NTHI 004 trial for Haemophilus infections (Prevention, In adults and the elderly with COPD) in United Kingdom and Sweden (NCT02075541)
  • 01 Jul 2014 Phase-II clinical trials in Haemophilus infections (Prevention, In adults and the elderly with COPD) in United Kingdom (IM)
  • 01 Jan 2014 GlaxoSmithKline completes a phase I trial in Haemophilus infections (in volunteers, prevention) in Belgium (NCT01678677)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top